El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

673149.pdf (1.51 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2017-08-21

Llicència de publicació

cc-by (c) Serrano Candelas, Eva et al., 2017
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/121965

Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41598-017-09361-4

Resum

Omalizumab (OmAb) is a humanized anti-IgE antibody approved for the treatment of chronic spontaneous urticaria (CSU). OmAb's mechanism of action is known to include actions on free IgE and on pre-bound IgE. However, OmAb is equally and rapidly effective against autoimmune and non-autoimmune urticaria where IgE involvement is not clear, suggesting the involvement of additional mechanisms of action. In this study, we sought to investigate the ability of OmAb to inhibit mast cell and basophil degranulation induced by sera from CSU patients. For this purpose, we performed a comparison between the in vitro incubation of sera from CSU patients treated with OmAb and the in vivo administration of OmAb in a clinical trial. We found that OmAb added in vitro to sera from CSU patients did not modify the ability of the sera to induce cell degranulation. Similarly, the sera from patients treated with OmAb in the context of the clinical trial who had a good clinical outcome maintained the capacity to activate mast cells and basophils. Thus, we conclude that the beneficial activity of OmAb does not correlate with the ability of patient sera to induce cell degranulation.

Matèries

Inflamació, Teràpia genètica, Urticària

Matèries (anglès)

Inflammation, Gene therapy, Urticaria

Citació

Col·leccions

Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

SERRANO CANDELAS, Eva, MARTÍNEZ ARANGUREN, Rubén, VEGA, Olga, GASTAMINZA, Gabriel, BARTRA TOMÀS, Joan, AUDICANA, Maria teresa, NÚÑEZ CÓRDOBA, Jorge m., ALGORTA, Jaime, VALERO, Antonio, MARTÍN ANDORRÀ, Margarita, FERRER, Marta. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells. _Scientific Reports_. 2017. Vol. 7, núm. 8985. [consulta: 8 de gener de 2026]. ISSN: 2045-2322. [Disponible a: https://hdl.handle.net/2445/121965]

Exportar metadades

JSON - METS

Compartir registre